The Radiochemistry and Molecular Imaging Probes (RMIP) Core Facility functions at the Intersection of the Cancer Center's laboratory research and clinical molecular Imaging initiatives - including cancer biology, medicine, chemistry, physics, radiochemistry, pharmacology and engineering, and is the largest manufacturing unit at MSKCC in terms of the number of clinical and research products produced. The RMIP Core Facility was established to provide investigators with radionuclides and to incorporate these radionuclides into radiolabeled diagnostic and/or therapeutic pharmaceuticals for both basic research investigations and patient formulations. The RMIP Core Facility consists of three major elements working closely together to provide the following services: (a) The Cyclotron Unit. Our MSKCC EBCO cyclotron on 72nd street produces 18F, 1241, 86Y and 89Zr, positron emitting radionuclides for research and clinical applications; (b) The Small Molecule Radiochemistry Section. This section incorporates cyclotron-produced positron-emitting radionuclides into radiochemicals and radiopharmaceuticals; (c) The Antibody Labeling Section. This section is responsible for the radiolabeling of peptides and monoclonal antibodies as requested by preclinical and clinical investigators for both cancer diagnostic and therapeutic purposes. MSKCC and the RMIP Core Facility have an outstanding reputation as a center for clinical translation of both imaging and therapeutic agents. Specifically, with regard to the translation of radiopharmaceuticals, over the past 20 years, the RMIP Core Facility has translated 37 radiopharmaceuticals for research clinical trials (imaging and therapy) in humans with radiolabeled antibodies, small molecules, nanoparticles and radiotherapeutics. To meet the growing programmatic demands and new federal regulations, MSKCC has implemented a significant investment In our radiochemistry facilities (to include GMP environments) over the next five years. The services provided by the RMIP Core have supported the research of 26 investigators in the past year. During the past grant period the work of the Core has contributed to 174 publications of researchers from 5 research programs.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-51
Application #
9204770
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
51
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hu, Zishuo Ian; Hellmann, Matthew D; Wolchok, Jedd D et al. (2018) Acquired resistance to immunotherapy in MMR-D pancreatic cancer. J Immunother Cancer 6:127
Warren, Shay; Kheterpal, Meenal; Myskowski, Patricia L et al. (2018) Unrelated immunodeficiency states may impact outcomes and immune checkpoint molecule expression in patients with mycosis fungoides: A clinicopathologic case-control study. J Am Acad Dermatol 78:530-539
Sanchez, Ana M; Shuman, Stewart; Schwer, Beate (2018) Poly(A) site choice and Pol2 CTD Serine-5 status govern lncRNA control of phosphate-responsive tgp1 gene expression in fission yeast. RNA 24:237-250
Saltsman, James A; Malek, Marcus M; Reuter, Victor E et al. (2018) Urothelial neoplasms in pediatric and young adult patients: A large single-center series. J Pediatr Surg 53:306-309
Choi, Karmel W; Shaffer, Kelly M; Zale, Emily L et al. (2018) Early Risk and Resiliency Factors Predict Chronic Posttraumatic Stress Disorder in Caregivers of Patients Admitted to a Neuroscience ICU. Crit Care Med 46:713-719
Kantor, Elizabeth D; Newton, Christina C; Giovannucci, Edward L et al. (2018) Glucosamine use and risk of colorectal cancer: results from the Cancer Prevention Study II Nutrition Cohort. Cancer Causes Control 29:389-397
Mizrachi, Aviram; Migliacci, Jocelyn C; Montero, Pablo H et al. (2018) Neck recurrence in clinically node-negative oral cancer: 27-year experience at a single institution. Oral Oncol 78:94-101
Fassel, Hannah; Bussel, James B; Roberts, Stephen S et al. (2018) Romiplostim for Immune Thrombocytopenia in Neuroblastoma Patients Receiving Chemotherapy. J Pediatr Hematol Oncol :
Lezcano, Cecilia; Shoushtari, Alexander N; Ariyan, Charlotte et al. (2018) Primary and Metastatic Melanoma With NTRK Fusions. Am J Surg Pathol 42:1052-1058
Bello, Danielle M; Russell, Christy; McCullough, Debbie et al. (2018) Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. Ann Surg Oncol 25:2884-2889

Showing the most recent 10 out of 8799 publications